All subjects (n = 23) | Low dose (N = 13) | High dose (N = 10) | |
---|---|---|---|
Number (proportion) of patients with serious adverse events | 7 (30.4%) | 4/13 (30.7%) | 3/10 (30%) |
Total number of SAE/SAR | 10 | 8 | 2 |
Number (proportion) of patients with non-serious adverse events | 23 (100%) | 13 (100%) | 10 (100%) |
Total number of non-serious adverse events | 93 | 54 | 39 |
Total number (proportion) of non-serious infections | 38 (40.8%) | 21 (38.8%) | 17 (43.5%) |